RecruitingNCT04871035
Immunoadsorption Versus Plasma Exchange for Treatment of Guillain-Barré Syndrome (GBS)
Studying Guillain-Barré syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Ulm
- Principal Investigator
- Johannes Dorst, ProfUniversity of Ulm
- Intervention
- Immunoadsorption(device)
- Enrollment
- 20 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2025
Study locations (1)
- Department of Neurology, University of Ulm, Ulm, Baden-Wurttemberg, Germany
Collaborators
DiaMed GmbH
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04871035 on ClinicalTrials.govOther trials for Guillain-Barré syndrome
Additional recruiting or active studies for the same condition.